rodatristat ethyl 600 mg BID

DRUG2 trials

Sponsors

Altavant Sciences GmbH

Conditions

HealthyPulmonary Arterial Hypertension

Phase 1

Multiple-Ascending Dose in Japanese Patients Bridging Study

CompletedNCT05065359

Altavant Sciences GmbHHealthy

Start: 2021-10-01End: 2022-03-30Updated: 2022-07-13

Phase 2

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

CompletedNCT04712669

Altavant Sciences GmbHPulmonary Arterial Hypertension

Start: 2021-03-15End: 2023-08-28Updated: 2025-06-04

Related Papers

Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial.

2024-09-1913 citations

A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2)

Pulmonary Circulation2022-04-0136 citations

ELEVATE 2: A multicenter study of rodatristat ethyl in patients with WHO Group 1 pulmonary arterial hypertension (PAH)

2021-09-056 citations